FEATURED SPECIAL REPORT >>
Yes, the business remains risky, but medical progress is stunning
Judging from Genentech's stellar performance, biotech might seem like a can't-miss investing opportunity
Charting the human genome was just the beginning. Now the focus is on creating pathways that lead to practical applications
The Institute of Regenerative Medicine believe's stem cells can repair cardiac damage
Some bold predictions on what's coming for the industry from Ernst & Young's Scott Morrison
A change in drug-approval procedures is a step toward avoiding more ImClone-style stock scandals
Additional Articles
